Status:
COMPLETED
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Lead Sponsor:
Mayo Clinic
Conditions:
Papillary Thyroid Cancer
Papillary Thyroid Microcarcinoma
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.
Detailed Description
Investigators plan to identify patients with small papillary thyroid carcinoma and subject such patients to radiofrequency ablation (RFA) therapy. Following RFA procedure patients will be monitored t...
Eligibility Criteria
Inclusion
- Are adults
- Nodule with Papillary thyroid carcinoma meeting the below criteria:
- Diagnosed by fine needle aspiration (FNA) cytology.
- Size \< 1.5 cm
- Non-surgical therapy is considered acceptable by the treating physician
- Radiology evaluation deems the lesion amenable to RFA therapy with minimal risk of complication
Exclusion
- Clinical evidence for a multifocal papillary thyroid malignancy
- Clinical evidence for local or distant metastatic disease
- Pregnancy
- Vocal cord paralysis on contralateral side
- Coagulopathy or patients on anticoagulation therapy
- Patients with prior neck surgery or neck radiation
- Patients with neck anatomy that precludes easy access by RFA
- Patients with comorbidities deemed too high of a risk for general anesthesia
- Treatment with another investigational drug or intervention (within 6 weeks of planned RFA).
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 7 2024
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04129411
Start Date
June 15 2020
End Date
May 7 2024
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905